+332.6%
OKLO vs GSK
+47.3%
+285.3%
-78.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.7% | +0.2% | -1.9% | -1.7% |
| 7D | +7.7% | -3.6% | +11.3% | +7.6% |
| 30D | -4.3% | -5.9% | +1.6% | -4.5% |
| 3M | -24.6% | -4.3% | -20.4% | -24.7% |
| 6M | -31.1% | -10.8% | -20.3% | -31.2% |
| YTD | -40.7% | +1.8% | -42.5% | -40.4% |
| 1Y | -42.4% | +23.5% | -65.9% | -42.3% |
| 3Y | +310.9% | +49.5% | +261.4% | +308.0% |
| 5Y | +332.6% | +49.7% | +283.0% | +330.9% |
| All | +332.6% | +47.3% | +285.3% | +330.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling